카메룬 - 프랑스어 - DPML (Direction de la Pharmacie du Médicament et des Laboratoires)

bb afrique sarl - soie tressÉ et enduit naturel non absobable chirurgicale - natural non absorbable surgical suture

캐나다 - 프랑스어 - Health Canada

vetoquinol n a inc - chloroxylénol - liquide - 2% - chloroxylénol 2% - miscellaneous local anti-infectives

벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aspen pharma trading ltd. - digoxine 0,5 mg/2 ml - solution injectable - 0,5 mg/2 ml - digoxine 0.5 mg - digoxin

벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aspen pharma trading ltd. - digoxine 0,05 mg/ml - solution buvable - 0,05 mg/ml - digoxine 0.05 mg/ml - digoxin

벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aspen pharma trading ltd. - digoxine 0,125 mg - comprimé - 0,125 mg - digoxine 0.12 mg - digoxin

벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aspen pharma trading ltd. - digoxine 0,25 mg - comprimé - 0,250 mg - digoxine 0.25 mg - digoxin

유럽 연합 - 프랑스어 - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agents contre la dermatite, à l'exclusion des corticostéroïdes - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

유럽 연합 - 프랑스어 - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinome, cellule squameuse - agents antinéoplasiques - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

유럽 연합 - 프랑스어 - EMA (European Medicines Agency)

mylan ire healthcare limited - fondaparinux sodique - venous thrombosis; pulmonary embolism; myocardial infarction; angina, unstable - agents antithrombotiques - 5 mg / 0. 3 ml et 2. 5 mg / 0. 5-ml solution for injectionprevention of venous thromboembolic events (vte) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery. prévention de la tev chez les adultes subissant une chirurgie abdominale qui sont jugées à haut risque de complications thrombo-emboliques, tels que les patients subissant abdominale, la chirurgie du cancer. prévention de la tev chez les adultes chez les patients médicaux qui sont jugées à haut risque de mtev et qui sont immobilisés en raison aiguë de la maladie, telles que l'insuffisance cardiaque et / ou respiratoire aiguë troubles, et / ou aiguë infectieuse ou inflammatoire de la maladie. traitement des adultes atteints aiguë symptomatique spontanée superficielles de la thrombose veineuse profonde des membres inférieurs sans administration concomitante de la thrombose veineuse profonde. 5 mg / 0. 5-ml solution for injectiontreatment of unstable angina or non-st-segment-elevation myocardial infarction (ua/nstemi) in adult patients for whom urgent (< 120 mins) invasive management (pci) is not indicated. du myocarde (idm) chez les patients adultes qui sont gérés avec les thrombolytiques ou qui, au départ, reçoivent aucune autre forme de thérapie de reperfusion. 5 mg / 0. 4-ml, 7. 5 mg / 0. de 6 ml et 10 mg/0. 8-ml solution for injectiontreatment of adults with acute deep-vein thrombosis (dvt) and treatment of acute pulmonary embolism (pe), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.

캐나다 - 프랑스어 - Health Canada

dechra ltd - chlorhydrate de lidocaïne monohydraté; chlorhydrate de bupivacaïne; bitartrate d'épinéphrine; cétrimide - solution - 40.6mg; 4.2mg; 0.025mg; 5mg - chlorhydrate de lidocaïne monohydraté 40.6mg; chlorhydrate de bupivacaïne 4.2mg; bitartrate d'épinéphrine 0.025mg; cétrimide 5mg - porcs